In this context, increased MYCN expression, a MYC-family transcription factor implicated in proliferation and differentiation programs in multiple cancers including neuroblastoma, may contribute to the aggressive proliferative phenotype of C2-GBM [57,58]. The gene discussed is MYC; the disease is glioblastoma.